{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:19:24Z","timestamp":1707524364420},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,26]]},"DOI":"10.7759\/cureus.17452","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T09:43:20Z","timestamp":1629971000000},"source":"Crossref","is-referenced-by-count":3,"title":["Role of Selective Sodium-Glucose Co-Transporter-2 Inhibitors in Managing Cardio-Renal Complications in Type 2 Diabetes Mellitus: Beyond Glycemic Control"],"prefix":"10.7759","author":[{"given":"Chike B","family":"Onyali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Comfort","family":"Anim-Koranteng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hira E","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitin","family":"Bhawnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aarthi","family":"Ethirajulu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almothana","family":"Alkasabera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihan A","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"WHO. diabetes fact sheet. (2021). Accessed: May 10, 2021: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2009.10.007","article-title":"Global estimates of the prevalence of diabetes for 2010 and 2030","volume":"87","author":"Shaw JE","year":"2010","unstructured":"Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010, 87:4-14. 10.1016\/j.diabres.2009.10.007","journal-title":"Diabetes Res Clin Pract"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.11.009","article-title":"Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: prevalence of and risk factors for diabetes mellitus in CKD in the Kidney Early Evaluation Program (KEEP)","volume":"57","author":"McFarlane SI","year":"2011","unstructured":"McFarlane SI, McCullough PA, Sowers JR, et al.. Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: prevalence of and risk factors for diabetes mellitus in CKD in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011, 57:S24-31. 10.1053\/j.ajkd.2010.11.009","journal-title":"Am J Kidney Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon O","year":"2019","unstructured":"Mosenzon O, Wiviott SD, Cahn A, et al.. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019, 7:606-17. 10.1016\/S2213-8587(19)30180-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal B","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al.. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017, 377:644-57. 10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-57. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014908","article-title":"Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"9","author":"Arnott C","year":"2020","unstructured":"Arnott C, Li Q, Kang A, et al.. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2020, 9:e014908. 10.1161\/JAHA.119.014908","journal-title":"J Am Heart Assoc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1917241","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"382","author":"Vieira JL","year":"2020","unstructured":"Vieira JL, Mehra MR. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020, 382:972-3. 10.1056\/NEJMc1917241","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13301","article-title":"Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers","volume":"20","author":"Dekkers CC","year":"2018","unstructured":"Dekkers CC, Petrykiv S, Laverman GD, Cherney DZ, Gansevoort RT, Heerspink HJ. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. 2018, 20:1988-93. 10.1111\/dom.13301","journal-title":"Diabetes Obes Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-020-10024-2","article-title":"Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors","volume":"26","author":"Margonato D","year":"2021","unstructured":"Margonato D, Galati G, Mazzetti S, Cannistraci R, Perseghin G, Margonato A, Mortara A. Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors. Heart Fail Rev. 2021, 26:337-45. 10.1007\/s10741-020-10024-2","journal-title":"Heart Fail Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13833","article-title":"A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes","volume":"21","author":"Halvorsen YC","year":"2019","unstructured":"Halvorsen YC, Walford GA, Massaro J, Aftring RP, Freeman MW. A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes. Diabetes Obes Metab. 2019, 21:2496-504. 10.1111\/dom.13833","journal-title":"Diabetes Obes Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.09.001","article-title":"Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes","volume":"38","author":"Heise T","year":"2016","unstructured":"Heise T, Jordan J, Wanner C, et al.. Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes. Clin Ther. 2016, 38:2265-76. 10.1016\/j.clinthera.2016.09.001","journal-title":"Clin Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1055\/a-0662-0209","article-title":"Effect of renal impairment on the pharmacokinetics and pharmacodynamics of tofogliflozin (a selective SGLT2 inhibitor) in patients with type 2 diabetes mellitus","volume":"69","author":"Ikeda S","year":"2019","unstructured":"Ikeda S, Takano Y, Schwab D, Portron A, Kasahara-Ito N, Saito T, Iida S. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of tofogliflozin (a selective SGLT2 inhibitor) in patients with type 2 diabetes mellitus. Drug Res (Stuttg). 2019, 69:314-22. 10.1055\/a-0662-0209","journal-title":"Drug Res (Stuttg)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019111168","article-title":"Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial","volume":"31","author":"Jardine MJ","year":"2020","unstructured":"Jardine MJ, Zhou Z, Mahaffey KW, et al.. Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial. J Am Soc Nephrol. 2020, 31:1128-39. 10.1681\/ASN.2019111168","journal-title":"J Am Soc Nephrol"},{"key":"ref16","unstructured":"American Urological Association. kidney: juxtaglomerular apparatus. (2021). Accessed: July 10, 2021: https:\/\/www.auanet.org\/education\/auauniversity\/education-products-and-resources\/pathology-for-urologists\/normal-histo...."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019010064","article-title":"Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS program","volume":"30","author":"Neuen BL","year":"2019","unstructured":"Neuen BL, Ohkuma T, Neal B, et al.. Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS program. J Am Soc Nephrol. 2019, 30:2229-42. 10.1681\/ASN.2019010064","journal-title":"J Am Soc Nephrol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30300-4","article-title":"Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial","volume":"8","author":"Oshima M","year":"2020","unstructured":"Oshima M, Neuen BL, Jardine MJ, et al.. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. Lancet Diabetes Endocrinol. 2020, 8:903-14. 10.1016\/S2213-8587(20)30300-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.22270\/jddt.v10i4.4154","article-title":"Acute renal injury: revisited","volume":"10","author":"El-Reshaid K","year":"2020","unstructured":"El-Reshaid K, Al-Bader S. Acute renal injury: revisited. J Drug Deliv Ther. 2020, 10:221-4. 10.22270\/jddt.v10i4.4154","journal-title":"J Drug Deliv Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner C","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al.. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016, 375:323-34. 10.1056\/NEJMoa1515920","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00686-z","article-title":"The pleiotropic effects of sodium-glucose cotransporter-2 inhibitors: beyond the glycemic benefit","volume":"10","author":"Patel DK","year":"2019","unstructured":"Patel DK, Strong J. The pleiotropic effects of sodium-glucose cotransporter-2 inhibitors: beyond the glycemic benefit. Diabetes Ther. 2019, 10:1771-92. 10.1007\/s13300-019-00686-z","journal-title":"Diabetes Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker TA","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al.. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019, 393:31-9. 10.1016\/S0140-6736(18)32590-X","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker TA","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al.. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019, 139:2022-31. 10.1161\/CIRCULATIONAHA.118.038868","journal-title":"Circulation"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi SE","year":"2018","unstructured":"Inzucchi SE, Zinman B, Fitchett D, et al.. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2018, 41:356-63. 10.2337\/dc17-1096","journal-title":"Diabetes Care"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART cardioLink-6 randomized clinical trial","volume":"140","author":"Verma S","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, et al.. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART cardioLink-6 randomized clinical trial. Circulation. 2019, 140:1693-702. 10.1161\/CIRCULATIONAHA.119.042375","journal-title":"Circulation"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2020.100039","article-title":"Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 holter analysis","volume":"7","author":"Garg V","year":"2020","unstructured":"Garg V, Verma S, Connelly KA, et al.. Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 holter analysis. Metabol Open. 2020, 7:100039. 10.1016\/j.metop.2020.100039","journal-title":"Metabol Open"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2020.02.005","article-title":"Effects of empagliflozin on left ventricular remodeling in patients with type 2 diabetes and coronary artery disease: echocardiographic substudy of the EMPA-HEART cardioLink-6 randomized clinical trial","volume":"33","author":"Bami K","year":"2020","unstructured":"Bami K, Gandhi S, Leong-Poi H, et al.. Effects of empagliflozin on left ventricular remodeling in patients with type 2 diabetes and coronary artery disease: echocardiographic substudy of the EMPA-HEART cardioLink-6 randomized clinical trial. J Am Soc Echocardiogr. 2020, 33:644-6. 10.1016\/j.echo.2020.02.005","journal-title":"J Am Soc Echocardiogr"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4644-9","article-title":"Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME\u00ae randomised trial","volume":"61","author":"Verma S","year":"2018","unstructured":"Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME\u00ae randomised trial. Diabetologia. 2018, 61:1712-23. 10.1007\/s00125-018-4644-9","journal-title":"Diabetologia"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01079-4","article-title":"Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study","volume":"19","author":"Katakami N","year":"2020","unstructured":"Katakami N, Mita T, Yoshii H, et al.. Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study. Cardiovasc Diabetol. 2020, 19:110. 10.1186\/s12933-020-01079-4","journal-title":"Cardiovasc Diabetol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00789-y","article-title":"Basic and clinical pharmaco-therapeutics of SGLT2 inhibitors: a contemporary update","volume":"11","author":"Kalra S","year":"2020","unstructured":"Kalra S, Shetty KK, Nagarajan VB, Ved JK. Basic and clinical pharmaco-therapeutics of SGLT2 inhibitors: a contemporary update. Diabetes Ther. 2020, 11:813-33. 10.1007\/s13300-020-00789-y","journal-title":"Diabetes Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon CP","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, et al.. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020, 383:1425-35. 10.1056\/NEJMoa2004967","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015716","article-title":"Effects of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and their combination on endothelial glycocalyx, arterial function, and myocardial work index in patients with type 2 diabetes mellitus after 12-month treatment","volume":"9","author":"Ikonomidis I","year":"2020","unstructured":"Ikonomidis I, Pavlidis G, Thymis J, et al.. Effects of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and their combination on endothelial glycocalyx, arterial function, and myocardial work index in patients with type 2 diabetes mellitus after 12-month treatment. J Am Heart Assoc. 2020, 9:e015716. 10.1161\/JAHA.119.015716","journal-title":"J Am Heart Assoc"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.03.009","article-title":"Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study","volume":"71","author":"Kosiborod M","year":"2018","unstructured":"Kosiborod M, Lam CS, Kohsaka S, et al.. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol. 2018, 71:2628-39. 10.1016\/j.jacc.2018.03.009","journal-title":"J Am Coll Cardiol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0517-7","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data","volume":"16","author":"Davies MJ","year":"2017","unstructured":"Davies MJ, Merton K, Vijapurkar U, et al.. Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data. Cardiovasc Diabetol. 2017, 16:40. 10.1186\/s12933-017-0517-7","journal-title":"Cardiovasc Diabetol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/64096-role-of-selective-sodium-glucose-co-transporter-2-inhibitors-in-managing-cardio-renal-complications-in-type-2-diabetes-mellitus-beyond-glycemic-control","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:29:59Z","timestamp":1707506999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/64096-role-of-selective-sodium-glucose-co-transporter-2-inhibitors-in-managing-cardio-renal-complications-in-type-2-diabetes-mellitus-beyond-glycemic-control"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,26]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.17452","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,26]]}}}